Quarterly report pursuant to Section 13 or 15(d)

Condensed Statements of Operations and Comprehensive Loss (Unaudited)

v3.23.3
Condensed Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Operating expenses:        
Research and development $ 13,787 $ 8,216 $ 38,019 $ 26,900
General and administrative 4,881 3,562 13,495 10,937
Total operating expenses 18,668 11,778 51,514 37,837
Loss from operations (18,668) (11,778) (51,514) (37,837)
Other income:        
Interest income 2,220 351 4,725 554
Net loss (16,448) (11,427) (46,789) (37,283)
Other comprehensive loss:        
Net unrealized (loss) income on available-for-sale investments, net of tax (18) 40 (21) (209)
Net comprehensive loss $ (16,466) $ (11,387) $ (46,810) $ (37,492)
Net loss per share of voting and non-voting common stock, basic $ (0.37) $ (0.39) $ (1.18) $ (1.29)
Net loss per share of voting and non-voting common stock, diluted $ (0.37) $ (0.39) $ (1.18) $ (1.29)